Is BMY a Buy Sell or Hold?
Bristol-Myers Squibb has received a consensus rating of Buy. The company’s average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.
Will BMY stock go up?
Will Bristol-Myers Squibb stock price grow / rise / go up? Yes. The BMY stock price can go up from 57.040 USD to 61.935 USD in one year.
Is Bristol-Myers Squibb a biotech company?
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation.
What does Bristol Myers Squibb do?
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Why is BMY stock so low?
However, BMY stock has seen a decline of over 10% since then, and it is down 11% over the last month (twenty-one trading days). The recent decline can be attributed to rising concerns over the Biden administration’s plan to reduce healthcare costs, including negotiating the drug prices in its Medicare program.
Why is BMY down so much?
Is BMY undervalued?
Bristol Myers Squibb is one of the largest pharmaceutical companies backed by a pristine Balance Sheet. Shares of BMY are vastly undervalued and present a tremendous opportunity for long-term investors. Investors earn a 3% dividend that was last increased over 9% in December of last year.
When did Bristol Myers merger with Squibb?
1989
In 1989 the merger of Bristol-Myers Company and Squibb Corporation—the descendant of a company founded by E.R. Squibb in 1858—created one of the world’s largest pharmaceutical companies.
What company did Bristol Myers buy?
Bristol Myers Squibb acquires Medarex, Inc., a biotech company and a partner since 2005. The acquisition significantly expands the company’s oncology and immunology pipeline.